TP53 and cardiomyopathy: In further support of the hypothesis that the p53-miR-18-HSF2-IGF-IIR2 pathway controls cardiomyopathy in the heart, we noted that miR-18 transgenic mice exhibited alleviated dilated cardiomyopathy and heart failure in vivo.